Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
LetterLetters to the Editor

Discriminating Ability of 18F-FET PET for Several Cerebral Neoplastic Lesions

Tomoyuki Kawada
Journal of Nuclear Medicine January 2014, 55 (1) 176; DOI: https://doi.org/10.2967/jnumed.113.128231
Tomoyuki Kawada
Nippon Medical School 1-1-5 Sendagi, Bunkyo-Ku Tokyo 113-8602, Japan. E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kawada@nms.ac.jp
  • Article
  • Info & Metrics
  • PDF
Loading

TO THE EDITOR: I read with interest the paper of Rapp et al. (1) recently published in The Journal of Nuclear Medicine. The study focused on the discriminatory ability of 18F-FET PET for the initial diagnosis of cerebral lesions suggestive of glioma. The data of 170 patients, excluding 4 with occult glioma, were used for the analysis. Glioblastoma and anaplastic glioma were defined as high-grade gliomas, and other gliomas including diffuse type were defined as low-grade gliomas. The numbers of high-grade gliomas, low-grade gliomas, lymphomas, and nonneoplastic lesions were 66, 77, 2, and 25, respectively.

I have concern about the authors’ statistical procedures, with special emphasis on receiver-operating-characteristic (ROC) curve analysis. The authors set 3 controls—nonneoplastic lesions, low-grade gliomas, and low-grade gliomas plus nonneoplastic lesions—to differentiate neoplastic lesions, high-grade gliomas, and high-grade tumor including lymphoma, respectively. They used the Youden index for cutoff values, which, for maximum and mean tumor-to-brain 18F-FET uptake ratios, were set at 2.5 and 1.9, respectively. The cutoff values were the same for differentiating neoplastic lesions, high-grade gliomas, and high-grade tumor including lymphoma. I think it would be difficult to use these cutoff values for the initial diagnosis of cerebral lesions. In general, patients with nonneoplastic lesions are set as controls, and cases of cerebral neoplastic lesions (total or specific) are determined using maximum and mean tumor-to-brain 18F-FET uptake ratios. The values in Table 2 and Figures 1 and 2 of Rapp et al. indicate a trend toward an increase in maximum and mean tumor-to-brain ratios as the malignancy of glioma progressed. But I feel that the third ROC curve analysis lacks a biologic basis (2). In addition, each area under the ROC curve was less than 0.8, which does not have sufficient statistical significance for satisfactory diagnostic performance in differentiating gliomas using maximum and mean tumor-to-brain 18F-FET uptake ratios.

Before the final conclusion of Rapp et al. on the advantage of 18F-FET PET for initial diagnosis of cerebral lesions is accepted, I strongly suggest further study by adding information on the diagnostic performance of the indicators Rapp et al. used. For example, they could not compare areas under the curve of high-grade gliomas and low-grade gliomas against nonneoplastic lesions by increasing the number of nonneoplastic lesion samples (3). Commercially based software such as MedCalc would be useful for conducting ROC curve analysis.

Footnotes

  • Published online ▪▪▪.

  • © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

REFERENCES

  1. 1.↵
    1. Rapp M,
    2. Heinzel A,
    3. Galldiks N,
    4. et al
    . Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013;54:229–235.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Pichler R
    . Being sensitive: to specify when amino acid tracers accumulate in a brain lesion [letter]. J Nucl Med. 2013;54:826.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Kawada T
    . Receiver operating characteristic curve analysis, sensitivity comparison and individual difference [letter]. Clin Radiol. 2012;67:940.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 55 (1)
Journal of Nuclear Medicine
Vol. 55, Issue 1
January 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Discriminating Ability of 18F-FET PET for Several Cerebral Neoplastic Lesions
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Discriminating Ability of 18F-FET PET for Several Cerebral Neoplastic Lesions
Tomoyuki Kawada
Journal of Nuclear Medicine Jan 2014, 55 (1) 176; DOI: 10.2967/jnumed.113.128231

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Discriminating Ability of 18F-FET PET for Several Cerebral Neoplastic Lesions
Tomoyuki Kawada
Journal of Nuclear Medicine Jan 2014, 55 (1) 176; DOI: 10.2967/jnumed.113.128231
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Business Model Beats Science and Logic: Dosimetry and Paucity of Its Use
  • Reply to “The Randomized, Phase 2 LuCAP Study”
  • Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!
Show more Letters to the Editor

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire